Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma

Next Previous
Trial Profile

A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QBS 10072S (Primary)
  • Indications Advanced breast cancer; Astrocytoma; Bladder cancer; Brain cancer; Brain metastases; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Malignant melanoma; Malignant thymoma; Malignant-mesothelioma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Sarcoma; Solid tumours; Tongue cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Quadriga BioSciences

Most Recent Events

  • 16 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 25 Oct 2022 According to an Quadriga BioSciences media release, the enrollment in the study has been completed.
  • 14 Sep 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top